Loading...
XASX
BIT
Market cap1mUSD
Jul 09, Last price  
0.00AUD
1D
0.00%
1Q
-33.33%
Jan 2017
-94.07%
IPO
-99.42%
Name

Biotron Ltd

Chart & Performance

D1W1MN
No data to show
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
9.33%
Rev. gr., 5y
-11.54%
Revenues
0k
-100.00%
0794,862402,45700000891,9511,722,4811,672,2651,548,1851,659,4791,622,5841,072,832803,0261,461,9451,558,5251,431,2830
Net income
-3m
L-1.61%
-1,883,575-2,198,973-3,234,004-1,882,093-1,776,099-1,872,244-1,907,527-2,378,052-3,850,745-3,085,814-2,723,221-3,004,303-3,093,405-1,593,645-1,611,799-3,575,959-3,194,347-2,781,083-3,492,766-3,436,524
CFO
-4m
L+8.47%
-1,710,695-1,787,424-3,645,129-1,622,319-1,892,243-1,858,310-1,968,741-2,287,852-3,090,611-2,975,848-2,719,700-3,080,907-2,833,497-1,842,011-1,497,891-3,081,822-3,407,597-2,436,048-3,290,035-3,568,566
Earnings
Aug 28, 2025

Profile

Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections. Biotron Limited was incorporated in 1999 and is headquartered in Sydney, Australia.
IPO date
Jan 24, 2001
Employees
4
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
1,431
-8.16%
Cost of revenue
5,061
5,831
Unusual Expense (Income)
NOPBT
(5,061)
(4,400)
NOPBT Margin
Operating Taxes
(1,645)
(1,431)
Tax Rate
NOPAT
(3,416)
(2,969)
Net income
(3,437)
-1.61%
(3,493)
25.59%
Dividends
Dividend yield
Proceeds from repurchase of equity
20
5,145
BB yield
-0.06%
-24.11%
Debt
Debt current
7
39
Long-term debt
7
13
Deferred revenue
Other long-term liabilities
Net debt
(433)
(3,986)
Cash flow
Cash from operating activities
(3,569)
(3,290)
CAPEX
(4)
Cash from investing activities
Cash from financing activities
(23)
5,533
FCF
(3,075)
(2,930)
Balance
Cash
393
3,984
Long term investments
54
54
Excess cash
447
3,967
Stockholders' equity
(244)
3,173
Invested Capital
7
45
ROIC
ROCE
2,136.40%
EV
Common stock shares outstanding
902,170
820,842
Price
0.04
46.15%
0.03
-57.38%
Market cap
34,282
60.63%
21,342
-51.73%
EV
33,850
17,356
EBITDA
(5,061)
(4,357)
EV/EBITDA
Interest
1
4
Interest/NOPBT